International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

Major Study Affirming the Relative Safety of Testosterone-replacement Therapy

Author(s): Biundo Bruce

Issue: Sep/Oct 2023 - Volume 27, Number 5
View All Articles in Issue

Page(s): 358-360

Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Page 1

Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Page 2

Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Page 3

Download in electronic PDF format for $75

Abstract: Between warnings from the U.S. Food and Drug Administration and many articles being published with the consensus that testosterone-replacement therapy had an increased cardiovascular risks in men, thereby questioning the relative safety of the therapy, the needs of hypogonadal (low testosterone) men, who also present with symptoms related to this condition, are much less likely to receive a treatment that can significantly improve their quality of life. This article discusses a major research project that determined that testosterone replacement therapy was no worse than a placebo in men with cardiovascular disease or at high risk for cardiovascular disease.

Related Keywords: testosterone replacement, androgenic hormone, hypogonadism, men, drug safety, cardiovascular health, U.S. Food and Drug Administration, FDA, black box warning, adverse effects, clinical trials, TRAVERSE trial, cardiovascular disease risk

Related Categories: HRT, ADVERSE DRUG EVENTS, CARDIOLOGY, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Biundo Bruce	Sep/Oct 2023 Pg. 358-360
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Allen W Chris, Greeson Nicole MH, Mixon William	Nov/Dec 2020 Pg. 451-458
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review Ruiz Andres D, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R	Jul/Aug 2011 Pg. 290-300
Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration Greeson Nicole MH, Mixon William, Allan W Chris	Jul/Aug 2020 Pg. 270-276
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 Deleruyelle Laura J	Sep/Oct 2016 Pg. 359-364
Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi	Jan/Feb 2015 Pg. 6-12
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K	Jan/Feb 2013 Pg. 74-85 View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Ford Gina, Garcia Lea	Jan/Feb 2001 Pg. 52-54
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Glaser Rebecca L, York Anne E	Jul/Aug 2019 Pg. 325-339
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Testosterone Replacement Therapy for Female Androgen Insufficiency Syndrome Tan Robert S	Jul/Aug 2005 Pg. 259-264 View Sample
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Gillson George R, Zava David T	Jul/Aug 2003 Pg. 250-256
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2 Deleruyelle Laura J	Nov/Dec 2016 Pg. 447-454
Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists Mixon Bill, Nain John	May/Jun 2013 Pg. 182-190
Return to Top